VivoSeq
Dermatology

Acne Vulgaris

0

Pipeline Programs↗

14

Active Trials↗

22

Companies Involved↗

Acne Vulgaris is an early-stage landscape with 0 programs across 22 companies. The most active players are Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd., Sun Pharmaceutical Industries, Inc., GSK.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

32/100

Mech. Concentration

N/A

Completion Rate

97/100

Attrition Rate

2/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Z

Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.

1 program

Phase 1Sun Pharmaceutical Industries, Inc. logo

Sun Pharmaceutical Industries, Inc.

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalAbbVie logo

AbbVie

0 programs

PreclinicalD

Dermata Therapeutics

0 programs

PreclinicalV

Vyne Therapeutics Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

180

clinical trials

Completed146 · 81%
Unknown status16 · 9%
Not yet recruiting8 · 4%
Recruiting4 · 2%
Withdrawn3 · 2%
Enrolling by invitation1 · 1%
Other2 · 1%

Clinical Trials

Trial Activity

180 trials

A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris
Recruiting·GGalderma R&D·Phase 3·NCT07186413·561 enrolled
Assessment of Serum Catestatin Level in Acne Vulgaris Patients
Recruiting·—·N/A·NCT07054398·60 enrolled
Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris
Recruiting·BBausch Health Americas, Inc.·N/A·NCT07205107·200 enrolled
Efficacy of Dihydroartemisinin for Treating Acne Vulgaris
Recruiting·SShanghai Zhongshan Hospital·Phase 1·NCT07007078·60 enrolled
Comparison of Efficacy of Azithromycin Alone vs Combination of Azithromycin and Probiotics in Management of Mild to Moderate Acne Vulgaris
Active, not recruiting·HHayatabad Medical Complex·Phase 4·NCT07384793·60 enrolled
Serum Intercellular Adhesion Molecule -1 in Acne Vulgaris Patients : Effect of Montelukast
Not yet recruiting·SSouth Valley University·Phase 3·NCT06340984·60 enrolled
Metronidazole 2% Gel Versus Clindamycin 1% Gel for Moderate Acne Vulgaris
Not yet recruiting·JJinnah Postgraduate Medical Centre·Phase 4·NCT07392047·60 enrolled
Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne Vulgaris
Not yet recruiting·JJiangxi Kvvit Pharmaceutical Co., Ltd.·Phase 2·NCT07345390·180 enrolled
The Relationship Between Microbioma Balance and Acne Vulgaris as a New Acne Treatment
Not yet recruiting·UUniversitas Padjadjaran·Phase 2·NCT06925386·64 enrolled
1% Clascoterone Cream for the Treatment Acne Vulgaris
Not yet recruiting·ZZhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.·Phase 3·NCT07457294·692 enrolled
Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris
Not yet recruiting·EEurofarma Laboratorios S.A.·Phase 3·NCT06905210·526 enrolled
Photodynamic Therapy With Topical Application of a Zn(II) Phthalocyanine (RLP068/Cl) and Red Light for the Treatment of Moderate-to-severe Acne Vulgaris
Not yet recruiting·UUniversità degli Studi di Brescia·N/A·NCT07089368·10 enrolled
Comparison of Efficacy of Topical Clascoterone With Topical Adapalene in the Treatment of Mild Acne Vulgaris
Not yet recruiting·KKhyber Teaching Hospital·Phase 1·NCT07673094·60 enrolled
Randomized, Triple-Blind, Placebo-Controlled Trial of Topical Dapsone Gel in Patients With Acne Vulgaris
Enrolling by invitation·—·Phase 4·NCT07244887·100 enrolled
Clinical Study to Evaluate Tolerability and Safety of FXFM244 and to Monitor Clinical Effect in Acne Vulgaris Patients
Completed·VVyne Therapeutics Inc.·Phase 2·NCT01362010·150 enrolled
Page 1 of 12

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)